MX2019008076A - Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. - Google Patents

Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.

Info

Publication number
MX2019008076A
MX2019008076A MX2019008076A MX2019008076A MX2019008076A MX 2019008076 A MX2019008076 A MX 2019008076A MX 2019008076 A MX2019008076 A MX 2019008076A MX 2019008076 A MX2019008076 A MX 2019008076A MX 2019008076 A MX2019008076 A MX 2019008076A
Authority
MX
Mexico
Prior art keywords
galactosidase
fabry
treatment
therapeutic regimen
alpha
Prior art date
Application number
MX2019008076A
Other languages
English (en)
Spanish (es)
Inventor
Almon Einat
CHERTKOFF Raul
Alon Sari
SHAALTIERL Yoseph
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of MX2019008076A publication Critical patent/MX2019008076A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022Alpha-galactosidase (3.2.1.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
MX2019008076A 2017-01-05 2018-01-05 Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada. MX2019008076A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762442537P 2017-01-05 2017-01-05
PCT/IL2018/050018 WO2018127920A1 (en) 2017-01-05 2018-01-05 Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase

Publications (1)

Publication Number Publication Date
MX2019008076A true MX2019008076A (es) 2019-08-29

Family

ID=62790830

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008076A MX2019008076A (es) 2017-01-05 2018-01-05 Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.

Country Status (14)

Country Link
US (2) US12194079B2 (enExample)
EP (1) EP3565583A4 (enExample)
JP (2) JP2020504131A (enExample)
KR (2) KR20190103320A (enExample)
CN (2) CN117959455A (enExample)
AU (1) AU2018205891B2 (enExample)
BR (1) BR112019013920A2 (enExample)
CA (1) CA3048151A1 (enExample)
CL (1) CL2019001867A1 (enExample)
IL (1) IL267863A (enExample)
MX (1) MX2019008076A (enExample)
NZ (1) NZ755725A (enExample)
WO (1) WO2018127920A1 (enExample)
ZA (1) ZA201904850B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12020820B1 (en) * 2017-03-03 2024-06-25 Cerner Innovation, Inc. Predicting sphingolipidoses (fabry's disease) and decision support
EA202290024A1 (ru) * 2019-06-11 2022-03-14 Амикус Терапьютикс, Инк. Способы лечения болезни фабри у пациентов с почечной недостаточностью
US20230416714A1 (en) * 2020-11-13 2023-12-28 Hanmi Pharm. Co., Ltd Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by fabry disease
IL302858A (en) * 2020-11-13 2023-07-01 Hanmi Pharm Ind Co Ltd Use of therapeutic enzyme fusion protein in prevention and treatment of renal diseases caused by or accompanied by fabry disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
CA2052728A1 (en) 1991-10-03 1993-04-04 Guy Ampleman Glycidyl azide polymer
EP1503788B1 (en) 2002-04-25 2011-06-29 Shire Human Genetic Therapies, Inc. Treatment of alpha-galactosidase a deficiency
JP5137814B2 (ja) * 2005-04-06 2013-02-06 ジェンザイム・コーポレーション 治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
CA2696699A1 (en) 2007-08-20 2009-02-26 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
WO2011061736A1 (en) 2009-11-17 2011-05-26 Protalix Ltd. Alkaline alpha galactosidase for the treatment of fabry disease
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
CN102933707B (zh) 2010-03-02 2015-09-30 普罗塔里克斯有限公司 稳定的α-半乳糖苷酶及其用途
RS60129B1 (sr) 2011-01-20 2020-05-29 Protalix Ltd Kompozicije alfa-galaktozidaze
WO2014120900A1 (en) 2013-01-31 2014-08-07 Icahn School Of Medicine At Mount Sinai Enhanced therapeutic regimens for treating fabry disease

Also Published As

Publication number Publication date
CL2019001867A1 (es) 2019-10-04
JP2020504131A (ja) 2020-02-06
WO2018127920A1 (en) 2018-07-12
ZA201904850B (en) 2022-04-28
US12194079B2 (en) 2025-01-14
CN117959455A (zh) 2024-05-03
RU2019124280A3 (enExample) 2021-09-14
IL267863A (en) 2019-09-26
US20250134968A1 (en) 2025-05-01
BR112019013920A2 (pt) 2020-02-04
KR20190103320A (ko) 2019-09-04
RU2019124280A (ru) 2021-02-06
AU2018205891B2 (en) 2024-11-07
NZ755725A (en) 2023-06-30
CN110381987A (zh) 2019-10-25
EP3565583A1 (en) 2019-11-13
JP2023022244A (ja) 2023-02-14
AU2018205891A1 (en) 2019-08-15
KR20240042110A (ko) 2024-04-01
US20200155654A1 (en) 2020-05-21
CA3048151A1 (en) 2018-07-12
EP3565583A4 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
Perez et al. Update on the use of immunoglobulin in human disease: a review of evidence
MX2019008076A (es) Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.
MX2022011334A (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert.
MX2023005455A (es) Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
MX2023012271A (es) Medicina terapeutica para enfermedades fibrosas.
HK1202776A1 (en) Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
EP3590338A3 (en) Medical treatments based on anamorelin
EP4523745A3 (en) Bis-choline tetrathiomolybdate for treating wilson disease
WO2019157056A8 (en) Treatment of patients with classic fabry disease
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
AU2020231505A8 (en) Sequential intravitreal administration of AAV gene therapy to contralateral eyes
WO2021007314A3 (en) Treatment of cancer
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
WO2019010301A8 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
MX379191B (es) Nuevo uso de clorhidrato de landiolol en el tratamiento a largo plazo de taquiarritmias e hipertension.
WO2021038500A3 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
EP4324522A3 (en) Methods of treating fabry patients having renal impairment
PH12021550656A1 (en) Methods for reducing the risk of diabetes in patients being treated for high cholesterol-related illnesses
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
HK1225969A1 (zh) 利用低剂量的拉喹莫德治疗克隆氏病
RU2417091C2 (ru) Способ лечения артрозо-артритов
RU2019131722A (ru) Способ инфузионной терапии при брахитерапии рака предстательной железы, выполняемой под спинальной анестезией
Willyard Companies compete over mutation-specific melanoma drugs
Piribauer Dermatosis toxica and phlebitis: case report